



**Contact:** Mark Spiecker  
**Location:** Aurora, Colorado, USA  
**Email:** mspiecker@sharklet.com  
**Tel:** 720-859-4070  
**Website:** www.sharklet.com



## Company Overview

**Industry Sector:** Medical Devices

**Company Overview:** Sharklet Technologies, Inc. has developed a revolutionary antibacterial surface technology. Aimed squarely at the challenges with microbial contamination, the Sharklet micro-pattern is applied to a variety of products, surfaces, and medical devices to inhibit bacterial colonization and reduce the clinical and economic burden of hospital-acquired infections.

**Target Market(s):** Major hospitals, medical device manufacturers, and OEMs worldwide.

## Management

### Leadership:

*Joseph W. Bagan*, Chairman of the Board  
*Mark M. Spiecker*, Chief Executive Officer  
*Dr. Anthony Brennan*, Chief Technology Officer  
*Kenneth Chung*, Director of Product Development  
*Dr. Shravanthi Reddy*, Director of Research

### Scientific Advisory Board:

*Anthony Brennan, Ph.D.*: Inventor of Sharklet and Endowed Professor in Materials Science and Biomedical Engineering at the University of Florida  
*Jaime Landman, M.D.*: Chair of Urology, UC Irvine  
*Daniel Perlman, M.D.*: President of Infectious Disease Society of America Colorado Chapter  
*Michael Pietrzak, M.D.*: Founder and President of Knowledge Management Solutions

## Key Value Drivers

**Technology\***: Inspired by the microorganism resistant properties of sharkskin, Sharklet™ is a patented surface technology comprised of millions of raised microscopic features arranged in distinct diamond shapes to form a continuous pattern. Each Sharklet diamond measures approximately 26 microns across and nearly three microns in feature height. Laboratory tests show that Sharklet can significantly reduce the attachment and survival of harmful pathogens including MRSA, VRE, and *Pseudomonas aeruginosa*.

**Competitive Advantage:** Sharklet™ relies solely on the shape and pattern of the surface alone to disrupt bacterial colonization, not toxic biocides that contribute to drug-resistant 'superbugs' such as MRSA. Sharklet is effective against a broad range of bacteria, easily incorporated into most polymer-based medical device, and not reliant upon humans' adherence to hygiene protocols.

**Plan & Strategy:** seeking strategic partners to commercialize medical devices and OEM devices.

\*Technology funded by the NIDDK and being commercialized under the NIH-CAP

## Product Pipeline

